SARC024
Regimen
- Experimental
- Regorafenib 160 mg/d 3-weeks-on/1-off
- Control
- Placebo with crossover at progression
Population
Metastatic osteosarcoma progressing on >=1 prior therapy, age >=18
Key finding
Regorafenib significantly delayed progression in relapsed osteosarcoma adults. No RECIST responses — benefit is disease stabilization, not tumor shrinkage. Toxicity typical of multi-TKI (HFSR, hypertension, fatigue).
Source: PMID 31013172
Timeline
Guideline citations
- NCCN BONE (p.32)